NeuroPace (NPCE) Competitors

MiMedx Group (NASDAQ:MDXG) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Do institutionals & insiders hold more shares of MDXG or NPCE?

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 1.7% of MiMedx Group shares are held by company insiders. Comparatively, 20.5% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Do analysts recommend MDXG or NPCE?

MiMedx Group presently has a consensus price target of $12.00, suggesting a potential upside of 62.05%. NeuroPace has a consensus price target of $16.60, suggesting a potential upside of 75.74%. Given NeuroPace's higher possible upside, analysts clearly believe NeuroPace is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
NeuroPace	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, MDXG or NPCE?

MiMedx Group has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500.

Which has preferable valuation and earnings, MDXG or NPCE?

MiMedx Group has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$348.88M	3.14	$42.42M	$0.21	35.26
NeuroPace	$79.91M	3.88	-$27.14M	-$0.84	-11.25

Is MDXG or NPCE more profitable?

MiMedx Group has a net margin of 8.84% compared to NeuroPace's net margin of -29.42%. MiMedx Group's return on equity of 23.03% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	8.84%	23.03%	17.09%
NeuroPace	-29.42%	-190.84%	-25.08%

Does the media favor MDXG or NPCE?

In the previous week, NeuroPace had 6 more articles in the media than MiMedx Group. MarketBeat recorded 10 mentions for NeuroPace and 4 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.98 beat NeuroPace's score of 0.94 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MiMedx Group beats NeuroPace on 9 of the 15 factors compared between the two stocks.